Posts

Although the pandemic gave a boost to the drug discovery market, accelerated development in the market will be influenced by effective use of data and analytics.

Matthew W. Reynolds, Ph.D., vice president, scientific affairs, real world solutions, IQVIA, explains how RWE can provide a greater picture of a disease’s progression as well as a blueprint for future outbreaks.

There has been an emphasis on the use of real-world data and real-world evidence in crafting messages for payers. But experts say the insights generated by RWD and RWE are extremely useful in understanding clinicians and patients.

As clinical stage biotech and pharmaceutical firms face unprecedented challenges in raising capital to fund their clinical trial program, strategic trade-offs are coming fast and furious. One of those at the top of the list is when and how to build a commercialization strategy, including navigating the complex work of securing market access.

Even with the COVID-19 emergency measures, payers still had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline, and were pondering new ways to pay for them. 

Med Ad News caught up with Fishawack Health CEO Jon Koch and Avalere Health President Elizabeth Carpenter to discuss the deal and why it took place, and what Avalere brings to Fishawack.